AHA op-ed in Medical Economics sets the record straight on 340B program growth and the role of drug companies
“As pharmaceutical companies throw stone after stone at the 340B program, they should beware of their own glass house. Their complaints ring hollow when it is clear that their own actions are driving growth in the program,” says an op-ed in Medical Economics authored by Bharath Krishnamurthy, AHA director of health policy and analytics, and Megha Parikh, AHA associate director of health analytics and policy.
“…Policymakers and the public should reject the fabrications perpetuated by pharmaceutical companies,” Krishnamurthy and Parikh write. “Instead, they should work to protect and support the 340B program and the benefits it affords to countless patients and communities across the country.”
Related News Articles
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…
Headline
The U.S. Court of Appeals for the 4th Circuit March 31 upheld a preliminary injunction issued by the U.S. District Court for the District of West Virginia…